Citigroup Inc Novavax Inc Call Options Transaction History

Citigroup Inc

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 12, 2024	SELL	$3.89 - $20.97 $2.35 Million - $12.7 Million	-604,800 Reduced 58.51%	428,900 $5.43 Million
Q1 2024 May 10, 2024	SELL	$3.76 - $6.02 $232,744 - $372,638	-61,900 Reduced 5.65%	1,033,700 $4.94 Million
Q4 2023 Feb 09, 2024	BUY	$4.8 - $7.67 $211,200 - $337,480	44,000 Added 4.18%	1,095,600 $5.26 Million
Q3 2023 Nov 09, 2023	BUY	$6.81 - $9.74 $5.07 Million - $7.25 Million	744,100 Added 241.98%	1,051,600 $7.61 Million
Q2 2023 Aug 10, 2023	BUY	$6.67 - $9.52 $875,104 - $1.25 Million	131,200 Added 74.42%	307,500 $2.28 Million
Q1 2023 May 11, 2023	BUY	$5.76 - $12.48 $203,328 - $440,544	35,300 Added 25.04%	176,300 $1.22 Million
Q3 2022 Nov 10, 2022	SELL	$18.2 - $76.12 $2.29 Million - $9.58 Million	-125,800 Reduced 47.15%	141,000 $2.57 Million
Q2 2022 Aug 10, 2022	BUY	$36.28 - $75.29 $881,604 - $1.83 Million	24,300 Added 10.02%	266,800 $13.7 Million
Q1 2022 May 12, 2022	SELL	$69.73 - $142.9 $11 Million - $22.6 Million	-158,000 Reduced 39.45%	242,500 $17.9 Million
Q4 2021 Feb 10, 2022	BUY	$134.56 - $217.97 $31.2 Million - $50.5 Million	231,600 Added 137.12%	400,500 $57.3 Million
Q3 2021 Nov 10, 2021	BUY	$177.8 - $270.58 $30 Million - $45.7 Million	168,900 New	168,900 $35 Million

286

84.8M

5.43M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $713M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.